Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.

Kim CY, Paek SH, Nam DH, Chang JH, Hong YK, Kim JH, Kim OL, Kim SH.

J Neurooncol. 2020 Feb;146(3):399-406. doi: 10.1007/s11060-019-03361-2. Epub 2020 Feb 4.

PMID:
32020470
2.

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.

Toms SA, Kim CY, Nicholas G, Ram Z.

J Neurooncol. 2019 Jan;141(2):467-473. doi: 10.1007/s11060-018-03057-z. Epub 2018 Dec 1.

3.

Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.

Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators.

J Neurooncol. 2017 Dec;135(3):545-552. doi: 10.1007/s11060-017-2601-y. Epub 2017 Aug 28.

4.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

5.

Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.

Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr.

J Med Econ. 2019 Oct;22(10):1006-1013. doi: 10.1080/13696998.2019.1614933. Epub 2019 May 20.

PMID:
31050315
6.

Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.

Kesari S, Ram Z; EF-14 Trial Investigators.

CNS Oncol. 2017 Jul;6(3):185-193. doi: 10.2217/cns-2016-0049. Epub 2017 Apr 12.

7.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

8.

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.

9.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R.

JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.

10.

What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?

Ornelas AS, Porter AB, Sharma A, Knox MG, Marks LA, Wingerchuk DM, O'Carroll CB.

Neurologist. 2019 Mar;24(2):71-73. doi: 10.1097/NRL.0000000000000222.

PMID:
30817495
11.

Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.

Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1106-1113. doi: 10.1016/j.ijrobp.2019.04.008. Epub 2019 Apr 23.

12.

The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.

Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI.

J Clin Neurosci. 2017 Feb;36:120-124. doi: 10.1016/j.jocn.2016.10.042. Epub 2016 Nov 16.

13.

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Guzauskas GF, Salzberg M, Wang BC.

CNS Oncol. 2018 Jul 1;7(3):CNS23. doi: 10.2217/cns-2018-0010. Epub 2018 Aug 20.

14.

Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.

Song A, Bar-Ad V, Martinez N, Glass J, Andrews DW, Judy K, Evans JJ, Farrell CJ, Werner-Wasik M, Chervoneva I, Ly M, Palmer JD, Liu H, Shi W.

J Neurooncol. 2020 Mar 23. doi: 10.1007/s11060-020-03466-z. [Epub ahead of print]

PMID:
32206976
15.

Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study.

Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Küng M.

Pancreatology. 2019 Jan;19(1):64-72. doi: 10.1016/j.pan.2018.10.004. Epub 2018 Oct 17.

16.

Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.

Mehta M, Wen P, Nishikawa R, Reardon D, Peters K.

Crit Rev Oncol Hematol. 2017 Mar;111:60-65. doi: 10.1016/j.critrevonc.2017.01.005. Epub 2017 Jan 22. Review.

17.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
18.

Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields.

Kessler AF, Linsenmann T, Westermaier T, Wolber W, Weiland J, Monoranu CM, Breun M, Hagemann C, Ernestus RI, Löhr M.

Oncol Lett. 2020 Jan;19(1):557-561. doi: 10.3892/ol.2019.11110. Epub 2019 Nov 19.

19.

Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.

Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis T, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Deuschl C, Sure U, Herrlinger U, Kebir S, Glas M.

J Cancer Res Clin Oncol. 2020 Mar;146(3):787-792. doi: 10.1007/s00432-019-03106-8. Epub 2019 Dec 11.

PMID:
31828428
20.

Tumor treating fields: a new standard treatment for glioblastoma?

Taillibert S, Le Rhun E, Chamberlain MC.

Curr Opin Neurol. 2015 Dec;28(6):659-64. doi: 10.1097/WCO.0000000000000250. Review.

PMID:
26551239

Supplemental Content

Support Center